Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
An antibacterial quinolone used in the treatment of urinary tract infections.
Oral administration 4 times a day.
Its use is authorized in infants from 3 months of age (Sanofi 2008).
It is excreted in breastmilk in clinically insignificant amounts (Traeger 1980), much lower than the dose used in infants.
Hemolysis has been observed in a newborn whose breastfeeding mother was taking nalidixic acid (Chin 2001 --> Belton 1965).
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity or glucose-6-phosphate dehydrogenase deficiency (WHO 2002).
The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to alteration of the intestinal flora (Ito 1993).
American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001).